Cdc25A and Cdc25B are over-expressed in many different primary human cancers [6,16] in the following percentages, respectively: breast cancer: 70% and 57%, thyroid cancer: 17–69% and 36–64%, hepatocellular cancer: 56% and 20%, ovarian cancer: 30% for both of them, colorectal cancer: 47–53% and 43–67%, non-Hodgkin’s lymphoma: 50% and 65%, laryngeal cancer: 41% and 57% and oesophageal cancer: 46–66% and 48–79% [17]. The gene discussed is CDC25B; the disease is cancer.